Efficacy and Safety Evaluation of Traditional Chinese Medicine in the Treatment of Advanced Colorectal Cancer
- Conditions
- Advanced Colorectal CancerTraditional Chinese Medicine
- Interventions
- Other: Traditional Chinese medicine herbalsOther: Western medicineOther: Integrated traditional Chinese and Western medicine
- Registration Number
- NCT02923622
- Brief Summary
Although patients of colorectal cancer use Traditional Chinese Medicine (TCM) herbal therapy extensively in China, no strong evidence exists to demonstrate the safety and survival outcomes of TCM herbal therapy combined with conventional western medicine for treatment of this disease. The purpose of this multi-center perspective cohort study is to evaluate the relationship between TCM herbal therapy and survival outcomes in patients with advanced colorectal cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 384
- histologically confirmed adenocarcinoma of the colon or rectum
- TNM classification of stage IV disease according to American Joint Committee on Cancer
- Between 18 and 80 years old
- Progression or inability undergone conventional chemotherapy (Conventional chemotherapy regimen containing fluorouracil, oxaliplatin, irinotecan based chemotherapy, and all the above regimen should be used before)
- Expected survival time is over 3 months
- Signed informed consent
- serious non-malignant diseases such as heart, renal, and hepatic illnesses
- the presence of other types of malignancies
- The patients can not take medicine for intestinal obstruction
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Traditional Chinese medicine group Traditional Chinese medicine herbals - Western medicine group Western medicine - Traditional Chinese and Western medicine combined group Integrated traditional Chinese and Western medicine -
- Primary Outcome Measures
Name Time Method Overall survival 3 years
- Secondary Outcome Measures
Name Time Method Progress free survival 3 years Quality of life as assessed by FACT-C v4.0 3 years Tumor control rate 3 years TCM syndrome score 3 years Number of participants with treatment-related adverse events as assessed by Chinese version of CTCAE v4.0 3 years
Trial Locations
- Locations (1)
Oncology Department of Xiyuan hospital of China Academy of Chinese Medical Sciences
🇨🇳Beijing, Beijing, China